Skip to Content

Superior efficacy of Iptacopan in PNH patients

Oral monotherapy with Iptacopan, a proximal complement inhibitor of factor B, has been compared with the standard of care with eculizumab or ravulizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH) and residual anemia. The superior effects of Iptacopan are elaborated by professor Régis Peffault de Latour, in this MEDtalk.

Régis Peffault De Latour

Få adgang til artiklen

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top